Table 2 Characteristics of the study population 3 months prior treatment initiation, at baseline and during follow-up period (6 and 12 months after first endobronchial infusion of ADSCs-SVF)
Characteristics | 3 months prior infusion | Baseline data | 6 months post-1stinfusion | 12 months post 1stinfusion |
|---|---|---|---|---|
Total number of patients | 5 | 14 | 14 | 14 |
Male | 4 | 12 | NA | NA |
Body weight (kgr) | 79.6±11.2 | 79.6±11.2 | 77.1±8.6 | 76.2±9.4 |
Age (yrs) | NA | 64.4±7 | NA | NA |
Ex smokers | 5 | 14 | NA | NA |
Current smokers | 0 | 0 | NA | NA |
Previous treatment with corticosteroids | 5 | 5 | NA | NA |
Other treatment (NAC) | 5 | 5 | NA | NA |
HRCT | 5 (typical UIP pattern) | 14 (typical UIP pattern) | NA | NA |
VATS | 2 (typical UIP pattern) | 6 (2 typical and 4 probable UIP pattern) | NA | NA |
Emphysema (HRCT) | 2 | 4 | NA | NA |
sPAP (mmHg) (cardiac echo) | 29.6 ±9 | 29.6 ±9 | 31.5±7 | 32.4±4 |
FVC%pred | 71.8 ±11.5 | 71.2±15.2 | 73.4 ± 18.1 | 74.4 ± 17.5 |
DLCO%pred | 45.82±9.5 | 48.4±11.1 | 48.9 ± 12.8 | 47.3 ± 12.9 |
6MWD | 501±67.9 | 472.1±55.2 | 477.1 ± 50.3 | 476.4 ± 51.9 |
mMRC | 2.0 ± 0.3 | 2.1 ± 0.6 | 1.7 ± 0.6 | 1.7 ± 0.4 |
SGRQ | NA | 35.1±6.8 | 27.8 ± 5.6* | 28.4 ± 5.7* |